InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs
NANJING, China, Dec. 20, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies against drug resistance, and Escugen, a clinical-stage antibody–drug conjugate (ADC) company, today announced that InxMed licensed EZWi-Fit® linker-payload platform from Escugen for the development of the next generation tumor-associated antigens (TAAs) targeting ADCs. The license agreement provides InxMed with right to use EZWi-Fit® platform on the several novel ADC...
Lynk Pharmaceuticals Announced First Rheumatoid Arthritis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001
BOSTON and HANGZHOU and SHANGHAI, China, Dec. 20, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has dosed the first patient with Rheumatoid Arthritis (RA) in a Phase Ⅲ clinical trial of its highly selective JAK1 inhibitor LNK01001. The clinical study is a randomized, double-blind, placebo-controlled Phase...
ShiraTronics Announces Landmark Achievement: World’s First Implant of its Innovative Chronic Migraine System
MINNEAPOLIS, Dec. 20, 2023 /PRNewswire/ -- ShiraTronics, Inc., a trailblazing clinical-stage medical device company, today announced a landmark achievement with the successful implantation of its Chronic Migraine System in the world's first six patients. This remarkable milestone represents a significant leap forward in neuromodulation, as the company unveils the first-ever fully...
Standigm named as a Tech Innovator in Generative AI in Drug Discovery use case
SEOUL, South Korea, Dec. 19, 2023 /PRNewswire/ -- Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, today announced that it has been included in a recent Gartner report, entitled, Emerging Tech: Tech Innovators for Generative AI NovelDrug Discovery. About Standigm's technology Standigm offers three complementary platforms for drug...
Parexel Recognized with Frost & Sullivan’s 2023 North American Customer Value Leadership Award for Impactful Real-world Evidence Solutions Addressing Customer Needs
Informing clinical development, enhancing the patient experience, mitigating risk and meeting health authority requirements across the product lifecycle are the foundation of Parexel's Real-world Evidence solutions SAN ANTONIO, Texas, Dec. 19, 2023 /PRNewswire/ -- Frost & Sullivan today recognized Parexel, one of the world's largest clinical research organizations (CROs), with the 2023 North American Customer Value Leadership Award following recent...
Burjeel Holdings Oncology Conference Marks 10 Years, Focusing on Equitable Solutions for Cancer Care
Experts stress collaboration and innovation are key to progress WASHINGTON, Dec. 19, 2023 /PRNewswire/ -- The 10th anniversary of the Burjeel Holdings Oncology Conference, held in partnership with Foreign Policy, brought together leading global experts to tackle the complex challenges of cancer care, emphasizing the need for multi-stakeholder collaboration. With cancer claiming millions...
New Drug Application of Mabwell’s 8MW0511 for Injection Accepted by NMPA
SHANGHAI, Dec. 19, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that the new drug application of its recombinant (yeast-secreted) human serum albumin-human granulocyte colony-stimulating factor (I) fusion protein for injection (R&D code: 8MW0511) has been accepted by the National Medical Products Administration (NMPA) for use in adult patients with non-myeloid malignant neoplasms to...
LTS receives $4.3 Million grant for the development of contraceptive Microneedle Array Patches
ANDERNACH, Germany, Dec. 19, 2023 /PRNewswire/ -- LTS, a leading pharmaceutical technology company, announced today that it has received a grant from the Bill & Melinda Gates Foundation. The purpose of the grant is to support the development of microneedle array patches (MAP) for self-administration of contraceptives for women in low- and middle-income countries (LMICs). The grant will fund $4.3...
Cutting-Edge Gut Microbiome Research: NOSTER’s latest solutions for comprehensive gut bacteria-based metabolite and microbiota analysis
KYOTO, Japan, Dec. 19, 2023 /PRNewswire/ -- Japan's Noster Inc., a premier provider of gut microbiome analysis services, is proud to unveil groundbreaking updates in its research on cutting-edge gut bacteria-based metabolite and gut microbiota analysis services. These advancements have far-reaching implications for research on human health and diseases such as diabetes, dietary supplement development, and innovative functional foods. Noster...
Paving the Way Towards a More Sustainable Future – Fullerton Health Accelerates Regional Growth with Sustainability Framework
SINGAPORE, Dec. 19, 2023 /PRNewswire/ -- Fullerton Health Group (FHG) continues to make important strides toward integrating its sustainability goals within its operations and ecosystem. The release of its FY2022 Sustainability Report underscores the Group's commitments and progress in achieving its sustainability goals. The report reflects FHG's strong partnerships and collective action...
